CenterBook Partners’s Revolution Medicines RVMD Stock Holding History

CenterBook Partners’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,769	Closed	-$561K	–	849
2026 Q1	$561K	Buy	+5,769	New	+$583K	0.03%	466

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

CenterBook Partners's RVMD Position: Q2 2026 in Review

CenterBook Partners sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 5,769 shares — an estimated $561K sold.

CenterBook Partners first reported a position in RVMD in Q1 2026 and held it in 1 quarter. The position peaked at $561K in Q1 2026. 692 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

CenterBook Partners reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
CenterBook Partners sold 5,769 Revolution Medicines shares in Q2 2026, an estimated $561K.
CenterBook Partners first reported a position in Revolution Medicines in Q1 2026 and held it in 1 quarter.
CenterBook Partners's Revolution Medicines position peaked at $561K in Q1 2026.
692 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.